AMITIZA

This brand name is authorized in Brazil, Japan, Singapore, United States

Active ingredients

The drug AMITIZA contains one active pharmaceutical ingredient (API):

1 Lubiprostone UNII 7662KG2R6K - LUBIPROSTONE

Lubiprostone is a locally acting chloride channel activator that enhances a chloride-rich intestinal fluid secretion without altering sodium and potassium concentrations in the serum. By increasing intestinal fluid secretion, lubiprostone increases motility in the intestine, thereby facilitating the passage of stool and alleviating symptoms associated with chronic idiopathic constipation (CIC). Read about Lubiprostone

Medication package inserts

Below package inserts are available for further reading:

Title	Information Source	Document Type
AMITIZA Capsule	FDA, National Drug Code (US)	MPI, US: SPL/PLR

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC code	Group title	Classification
A06AX03	Lubiprostone	A Alimentary tract and metabolism → A06 Laxatives → A06A Laxatives → A06AX Other laxatives
Discover more medicines within A06AX03

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country	Identification scheme	Identifier(s)
Country: BR	Câmara de Regulação do Mercado de Medicamentos	Identifier(s): 501120060029907, 501120060030007, 501120060030107, 501120060030207, 501120060030307, 501120060030407, 501120060030507, 501120060030607
Country: JP	医薬品医療機器総合機構	Identifier(s): 2359006M1025, 2359006M2021
Country: SG	Health Sciences Authority	Identifier(s): 15329P, 15330P
Country: US	FDA, National Drug Code	Identifier(s): 35356-500, 63629-6398, 64764-080, 64764-240